Skip to Main Content

aTyr Pharma, Inc. (NASDAQ: ATYR) Securities Fraud Class Action

View Complaint
CompanyaTyr Pharma, Inc.
CourtUnited States District Court for the Southern District of California
Case Number3:25-cv-02681 and 3:25-cv-02826
JudgeHonorable William Q. Hayes and Honorable Benjamin Jerome Cheeks
Class PeriodNovember 7, 2024 through September 12, 2025
Security TypeCommon Stock

LEAD PLAINTIFF DEADLINE IS DECEMBER 8, 2025.

If you have suffered losses and would like to discuss your rights, please fill out this form or you may contact Jonathan Naji, Esq. at (484) 270-1453 or via e-mail at info@ktmc.com.

Case Background:
Class action lawsuits have been filed on behalf of those who purchased or otherwise acquired aTyr Pharma, Inc. (“aTyr”) (NASDAQ: ATYR) common stock between November 7, 2024 and September 12, 2025, inclusive (the “Class Period”).

aTyr is a clinical stage biotechnology company focused on innovative therapeutic interventions. Since late-2022, aTyr has been conducting a Phase 3 study to evaluate the safety and efficacy of intravenous Efzofitimod (“EFZO-FIT”) in patients with pulmonary sarcoidosis (the “EFZO-FIT Study”).

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company’s business, operations, and prospects.  Specifically, Defendants misrepresented and/or failed to disclose that: (1) the design of the EFZO-FIT Study would not permit the company to fully remove steroids from each patient’s treatment plans as claimed by Defendants; (2) there may be external factors that permit patients to completely remove oral corticosteroids from their treatment plans, undercutting the efficacy of Efzofitimod and the undermining the results of the EFZO-FIT Study; and (3) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

What is a Lead Plaintiff?

A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Filling out the online form above or communicating with any counsel is not necessary to participate or share in any recovery achieved in this case.  Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

Complete this form with your transactions in aTyr Pharma, Inc. common stock between November 7, 2024 and September 12, 2025.

Click Here to Print PDF of this Form

SUBMIT YOUR INFORMATION
* Denotes required field
Date
# of Shares
Price per Share
Date
Principal Amount
Amount Paid
Series or CUSIP
Date
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of aTyr Pharma, Inc. prior to the Class Period?
Are you a current or former employee of aTyr Pharma, Inc. ?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter.
Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By submitting this form, you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC disclaimer
I would like to receive new case alerts by email